|Over a month ago|
Immucell reports preliminary Q2 revenue $3.9M vs. $4.5M last year » 06:3507/0707/07/22
"A material disruption in the supply to us of needed plastic parts limited our production and sales during the quarter," commented Michael Brigham, President and CEO of ImmuCell. "We had a backlog of orders worth approximately $704,000 as of June 30, 2022 that all could have been shipped to customers erasing this drop in sales for the quarter, if not for this supply disruption that we are working to resolve during the third quarter. The strategic investments we are making to incrementally expand our First Defense manufacturing capacity further to approximately $30 million per year during the third quarter and to approximately $35 million per year during the fourth quarter are on track. Our work to achieve regulatory approval to commercialize Re-Tain continues. We expect a response from the FDA during the third quarter to our submission of the final Technical Section required to complete our New Animal Drug Application, and we have submitted our responses to all of the findings from a recent pre-approval inspection by the FDA."
|Over a quarter ago|
Fly Intel: After-Hours Movers » 18:0104/1104/11/22
TSRI, BDSX, ICCC, XMTR, UIHC, ICLR, AEI, HOTH, EDSA, QSR, DNUT, SBUX
Check out this evening's…
Immucell reports preliminary Q1 revenue $6M vs. $4.1M last year » 16:0904/1104/11/22
"Sales during the…
"Sales during the first quarter ended March 31, 2022 increased by 46% to $6.0 million compared to the same period of the prior year, which is exciting for us," commented Michael Brigham, president and CEO of ImmuCell. "This favorable comparison does reflect tighter supply constraints during the first quarter of 2021 before the first level of investments to increase our production capacity had been completed."